stockrow
Friday 6 November 2026
Export ADMA’s income statement to Excel — free account
ADMA Biologics Inc
ADMA Healthcare Biotechnology
ADMA Biologics Inc’s revenue for fiscal 2025 (year ended December 2025) was $510.2 million, up 19.6% from fiscal 2024.
- Revenue
- +5.12%
- EPS
- +46.7%
- Free cash flow
- +1,709.5%
- Total debt
- +140.5%
Quarter to September 2026, against a year earlier
13.03
0.18
−1.36%
Follow ADMA
Alert me
| Sep '26 From the 10-Q filed 4 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
12.70 | 11.63 | 13.06 | 29.90 |
+8 more quarters Free account |
P/S ratio |
4.32 | 3.73 | 4.17 | 8.52 | |
P/FCF ratio |
18.66 | 16.44 | 18.90 | 158.03 | |
P/Operating CF |
129.18 | 64.67 | 36.52 | 121.96 | |
P/B ratio |
5.12 | 4.68 | 5.45 | 9.11 | |
Price to Tangible BV |
5.17 | 4.73 | 5.51 | 9.19 | |
EV/Sales |
4.47 | 3.85 | 4.29 | 8.50 | |
EV/EBITDA |
9.96 | 8.48 | 9.80 | 21.66 | |
EV/Operating CF |
16.47 | 14.43 | 17.06 | 86.02 | |
EV/FCF |
19.28 | 16.98 | 19.45 | 157.61 | |
Quick Ratio |
3.08 | 3.62 | 3.73 | 3.54 | |
Current Ratio |
6.04 | 6.97 | 6.95 | 6.71 | |
Net Debt/EBITDA |
0.00 | 1.16 | 1.03 | (0.18) | |
Debt/Assets |
0.00% | 29.07% | 30.06% | 12.17% | |
Debt/Equity |
0.00 | 0.49 | 0.51 | 0.16 | |
Asset Turnover |
0.80 | 0.82 | 0.87 | 0.92 | |
Operating CF/Net income |
0.35 | 0.78 | 1.29 | 0.72 | |
Capex/Depreciation |
0.00 | (3.74) | 1.21 | (0.58) | |
Interest Coverage |
19.74 | 15.32 | 27.75 | 38.59 | |
Research and Development Expense of Revenue |
3.18% | 4.83% | 2.27% | 0.99% | |
Selling, General and Administrative Expense of Revenue |
18.82% | 21.49% | 23.36% | 16.89% | |
Intangible Assets out of Total Assets |
0.01 | 0.01 | 0.01 | 0.01 | |
Share Based Compensation of Revenue |
4.40% | 4.93% | 5.53% | 3.87% | |
Graham Net Nets |
0.13 | 0.13 | 0.11 | 0.07 | |
Graham Number |
5.90 | 5.38 | 5.07 | 5.24 | |
Earnings Yield |
7.88% | 8.60% | 7.66% | 3.34% | |
Free Cash Flow Yield |
5.36% | 6.08% | 5.29% | 0.63% | |
Revenue per Share |
0.63 | 0.55 | 0.49 | 0.58 | |
Operating CF per Share |
0.08 | 0.13 | 0.25 | 0.15 | |
Capex per Share |
0.00 | (0.03) | 0.01 | (0.01) | |
Free Cash Flow per Share |
0.08 | 0.10 | 0.26 | 0.14 | |
Cash per Share |
0.56 | 0.60 | 0.59 | 0.37 | |
Shareholders Equity per Share |
1.96 | 1.79 | 1.65 | 2.00 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.96 | 1.79 | 1.65 | 2.00 | |
Free Cash Flow |
17.30 | 22.28 | 60.65 | 34.36 | |
Working Capital |
480.59 | 452.45 | 437.63 | 396.97 | |
Capital Expenditures |
(0.07) | (7.26) | 2.40 | (1.28) | |
Net Current Asset Value |
281.88 | 252.20 | 236.31 | 319.59 | |
EV/EBIT |
9.61 | 8.79 | 10.19 | 22.64 | |
Capex to Sales |
0.00 | 0.06 | (0.02) | 0.01 | |
Price to Operating Income |
9.30 | 8.51 | 9.90 | 22.70 | |
| Other line items | |||||
Average Receivables |
153.45 | 123.98 | 117.64 | 104.21 | |
Average Payables |
29.84 | 30.75 | 20.57 | 21.37 | |
Average Inventory |
231.39 | 215.39 | 197.14 | 188.35 | |
Average Assets |
650.59 | 621.30 | 587.88 | 556.46 | |
Average Common Equity |
434.85 | 403.27 | 381.87 | 413.17 |
Columns are period end dates · fundamentals updated 4 Nov 2026